Biotechnology

Invetech Named Victorian Top Exporter of the Year

MELBOURNE, Australia, Oct. 30, 2021 /PRNewswire/ -- Invetech, an end-to-end commercialisation partner to world's foremost therapeutic and diagnostic companies, has been named the Victorian Exporter of the Year at the2021 Governor of Victoria Export Awards (GOVEA). Invetech also won the Internatio...

2021-10-30 05:35 4329

Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia

-- Application marks the first protein-based COVID-19 vaccine submitted to regulatory authorities for provisional approval inAustralia  -- In addition to today's submission to the Therapeutic Goods Administration, the company recently filed for authorization with MHRA, with additional filings in...

2021-10-29 19:15 6712

Operating Income of Yiling Pharmaceutical in First 3 Quarters Reaches CNY 8.112 Billion, Up 25.81%

SHIJIAZHUANG, China, Oct. 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical released the three-quarter report on the evening ofOctober 28. In the first three quarters, the operating income of the company reachedCNY 8.112 billion, up 25.81% year on year; the net profit attributable to shareholders of...

2021-10-29 17:17 1924

Appendix 4C - Q1 FY22 Quarterly Cash Flow Report

Highlights: * New details on ATH34 Phase 2 clinical trial released. * Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress. * Expanded intellectual property portfolio positions future opportunities. * Cash balance as of 30 September 2021 of A$41.3M....

2021-10-29 14:50 2896

Aiming for Global CDMO, Xcell Therapeutics opens an export route to 62 countries with cell therapy culture technology.

SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- In a hair follicle, there are "dermal follicle papilla cells" that appear 3,000 grapes clustered together. The name was given because its outline resembles the papilla of the human body when observed under a microscope. Hair loss occurs when der...

2021-10-28 21:00 1713

HanAll Biopharma Reports Third Quarter 2021 Results

* Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year * Q3'21 operating profit of KRW 2.2 billion grew by 120% compared to Q3'20 * Nine months sales of KRW 76.7 billion and operating profit of KRW 9.2 billion rose by 15% and 67% YoY, repectively SEOUL, South Korea, Oct...

2021-10-28 21:00 2515

WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility

- Successfully completed nearly 20 regulatory inspections in total, including 13 regulatory inspections since the start of 2021 WUXI, China, Oct. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced th...

2021-10-28 08:30 2481

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), in a Two Drug Regimen, Proves Safe and Effective for Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 20:47 1390

I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China

* I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors acrossChina. * I-Mab is on track to submit BLA for third line multiple myeloma (MM) treatment by Q4 2021. * The...

2021-10-26 20:00 3170

Samsung Biologics Reports Third Quarter 2021 Financial Results

* Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. * Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20. * Stable supply, strong operational excellence and a high utilization rate across all plants. * Active investment on expansion, pre-sales ac...

2021-10-26 15:23 2335

Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818

JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd. ("Angel Pharma") today announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation (CDE) to initiate clinical trials in pati...

2021-10-26 07:30 2142

SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage

SEOUL, South Korea, Oct. 25, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 inAustralia. In the Phase 2a trial of a two stage adaptive design ...

2021-10-25 20:30 2191

Happiness Biotech Acquires Majority Ownership in Fujian Shennong

NANPING, China, Oct. 25, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), aChina-based company engaging in the business of production of nutraceutical and dietary supplements, providing e-commerce solutions, and the sales of automobile, today announced that it...

2021-10-25 20:00 3271

Meet the Next Resolution in Medicine -- Polaris Biology Releases Starion™, the next-generation mass cytometer

SHANGHAI, Oct. 23, 2021 /PRNewswire/ -- Polaris Biology, a leading innovator in single-cell technologies, announced today the largest product launch in company history with the introduction of the Starion™ Mass Cytometry System. Dr. Yuzhang Wu, and...

2021-10-23 15:05 3454

2021 Bio-enzyme Application Explorer Summit held in Chengdu

The event focuses on innovation and development of biochemical pharmaceuticals CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment inChina and abroad. On Octobe...

2021-10-22 14:23 1799

Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore

SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withIncyte Biosciences  International Sàrl,the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and onc...

2021-10-22 09:00 2198

Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray

SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (''Shandong Luoxin''), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. ("Luoxin Pharmaceutical" or "the company")    , signed a licensing agreement withAustria-based Marinomed Biotech AG ("Mar...

2021-10-21 15:58 1892

GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research

PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed inPerth, Aus...

2021-10-21 08:05 2278

Bridge Biotherapeutics Announces Initiation of the Phase I Clinical Trial for BBT-401 in China

* China Phase I study of BBT-401 had its first subject dosed in Chengdu, China * The company seeks to accelerate its business development activities with Daewoong, their partner for the development and commercialization of BBT-401 in 22 Asian countries SEONGNAM, South Korea and CHENGDU, China, ...

2021-10-20 07:00 2076

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology c...

2021-10-20 05:08 2425
1 ... 153154155156157158159 ... 165

Week's Top Stories